Hypertension

The Leading Modifiable Risk Factor for Early Death and Disability[1]

Uncontrolled Hypertension and Health Risks

For every 10 mmHg SBP decrease

There is a **20-30% reduction** in the risk of **cardiovascular events** (e.g., stroke, myocardial infarction, heart failure)[2]

The more (≥3) antihypertensive agents

The greater the risk for a patient with uncontrolled hypertension of **CVD**, **myocardial infarction**, or **stroke**[a,3]

Despite availability of antihypertensive agents

Patients still have **uncontrolled hypertension** (≥130/80 mmHg) despite **receiving multiple medications**[b,4]

Patients Uncontrolled on Antihypertensives (%) per Number of Medications



ACE inhibitor, ARB, CCB, and/or diuretics

There is a **need** for further blood pressure control by targeting **additional pathways**[5]

[a]Data from the Reduction of Atherothrombosis for Continued Health (REACH) registry, including 53,530 hypertensive patients; [b]Retrospective analysis of the Optum® Electronic Health Record Database evaluated patients ≥18 years of age with a diagnosis of hypertension (N=207,705) classified based on the number of prescribed antihypertensive medication classes (3, 4, or ≥5).

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB , calcium channel blocker; CVD, cardiovascular disease; SBP, systolic blood pressure.

References: 1. Institute for Health Metrics and Evaluation (IHME). *Findings from the Global Burden of Disease Study 2017.* Seattle, WA: IHME; 2018. 2. Ettehad D, et al. *Lancet.* 2016;387(10022):957-967. 3. Kumbhani DJ, et al. *Eur Heart J.* 2013;34(16):1204-1214. 4. Ammann EM, et al. *Heliyon.* 2023;9(2):e13258. 5. Nejad SH, et al. *Curr Hypertens Rep.* 2023;25(10):343-352.

Hypertension

Targeting the Endothelin Pathway Has Emerged as a Novel Approach in the Management of Hypertension[1,2]



The **endothelin system** is a pathway that can provide **complementary blood pressure control** for patients with uncontrolled hypertension

ACEI, angiotensin-converting enzyme inhibitor; **ARB**, angiotensin receptor blocker; **ERA**, endothelin receptor antagonist; **ET-1**, endothelin-1; **MRA**, mineralocorticoid receptor antagonist; **RAAS**, renin-angiotensin-aldosterone system.

References: 1. Kumbhani DJ, et al. *Eur Heart J.* 2013;34(16):1204-1214. **2.** Clozel M, et al. *Can J Physiol Pharmacol.* 2022;100(7):573-583.